LJ International Inc. JADE 深 滬
已收盤 12-24 16:00:00 美东时间
62.2584
+0.163
+0.26%
華盛通- 最 高62.31
- 今 開62.31
- 成交量 360股
- 最 低 62.225
- 昨 收 62.0954
- 總市值 1867.75万
- 52周最高 62.5239
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 40.7433
- 委 比 0.00%
- 總股本 30.00万
- 歷史最高 62.5239
- 量 比 0.07
- 振 幅 0.14%
- 歷史最低 40.7433
- 每 手 1
- 風險率 5.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Road Investments Alters Board Appointment Plans
Jade Road Investments ( ($GB:JADE) ) has issued an update. Jade Road Investment...
11-04 01:32
Jade Biosciences To Present New Preclinical Safety, Translational Data For Immunoglobulin A Nephropathy Candidate JADE101 American Society of Nephrology Kidney Week
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing
10-18 04:09
Jade Biosciences Announces $135 Million Private Placement
Jade Biosciences announced aPIPE financing of approximately $135 million, involving both new and existing investors. The transaction includes13,368,164shares of common stock at $9.14 per share and pre-funded warrants for1,402,092shares. Proceeds will support research and development, and are expected to fund operations into 2028. The company also entered a registration rights agreement with investors.
10-07 11:00
Jade Biosciences Starts Phase 1 Trial Of JADE101 Antibody For IgA Nephropathy, Eyes 2026 Data
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has dosed the first
09-02 19:03
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
A clinical-stage biotechnology company, Jade Biosciences, has initiated a Phase 1 trial for JADE101, a monoclonal antibody targeting APRIL for IgAN treatment. JADE101 shows high binding affinity and potential for infrequent dosing. Mid-2026 interim data will guide dose selection based on biomarkers.
09-02 11:00
业聚医疗（6929.HK）：营收净利双增，全球化与创新双轮驱动
2025年，全球化依然是医疗器械行业发展的主旋律。而心血管介入领域的先行者——业聚医疗，凭借前瞻性的全球化布局，在地缘政治的复杂变局下，仍能深入超70个国家和地...
08-18 08:54
Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences announced its participation in two upcoming investor conferences. CEO Tom Frohlich and CSO Andrew King will discuss the company's pipeline, including JADE101 for immunoglobulin A nephropathy, at the H.C. Wainwright Kidney Virtual Conference on July 14 and the Stifel Biotech Summer Summit on August 13. Both events will include fireside chats and one-on-one investor meetings. Jade is focused on developing best-in-class therapies fo...
07-08 11:00
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences, Inc., a biotech company focused on autoimmune diseases, has appointed Brad Dahms as its Chief Financial Officer. Dahms, with a strong track record in biotech finance and strategic leadership, joins Jade to support its growth, including advancing its lead candidate JADE101 for IgA nephropathy into clinical trials in 2025. His prior experience includes roles at IDRx, Theseus Pharmaceuticals, and Selecta Biosciences, where he led f...
07-01 11:00
Jade Road Investments Delays 2024 Annual Report
Jade Road Investments ( ($GB:JADE) ) has provided an announcement. Jade Road In...
07-01 03:46
Jade Biosciences Presents Detailed Preclinical Characterization Of JADE101 In Development For IgAN, Chronic Autoimmune Kidney Disease; First-In-Human Trial Expected To Begin H2 2025
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppressionIn non-human primates, JADE101 showed a differentiated
06-09 19:03
